Andreas Trumpp

German Cancer Research Center — Germany

Medicine · Health Sciences

88h-index33.1kcitations684works6.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(164), Cancer Cells and Metastasis(102), Hematopoietic Stem Cell Transplantation(75), Chronic Myeloid Leukemia Treatments(71), Cancer Genomics and Diagnostics(67)

Publications683 total

Supplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Data from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Ultra-Content Screening (UCS): Toward the Big Blood Picture
2026Open Access
Genotype-phenotype mapping identifies fetal-like CD55 <sup>+</sup> immunoregulatory cancer cells as mediators of immune escape in colorectal cancer
2026Open Access
Supplementary Figures from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2026Open Access
Supplementary Tables from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2026Open Access
Supplementary Figure 2 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
page 1 of 35Next →

Frequent Co-authors

Marieke Essers(10), Anne Wilson(8), Simon Haas(8), Corinna Klein(6), Martin R. Sprick(5), Simon Raffel(5), Petra Zeisberger(5), Elisa Laurenti(4), William Blanco-Bose(4), H. Robson MacDonald(4), Ido Amit(4), Lars Velten(4), Thórdur Óskarsson(4), Michael D. Milsom(4), Nina Cabezas‐Wallscheid(4), Carl Herrmann(4), Gabriela Oser(3), Maike Jaworski(3), Franziska Paul(3), Andreas Schneeweiß(3)